Met 326IIe aminoacid polymorphism in the human p85α gene has no major impact on early insulin signaling in type 2 diabetes

Hormone and Metabolic Research

Volumn 36, Issue 10, 2004, Pages 686-692

  Algenstaedt, P ^a,b   Hennigs, N ^a   Telkamp, N ^a   Schwarzloh, B ^a   Kausch, C ^c   Matthaei, S ^d   Hansen Algenstaedt, N ^b   Greten, H ^a  

^a Medizinische Klinik I   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Christliches Krankenhaus Quakenbruck   (Germany)

Author keywords

Insulin action; Mutation; PI 3 kinase; SNP; Type 2 diabetes

Indexed keywords

AMINO ACID; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P85; PROTEIN P85 ALPHA; UNCLASSIFIED DRUG; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE 2 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CODON; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE MUTATION; GENETIC CONSERVATION; GENETIC VARIABILITY; GLUCOSE TRANSPORT; HETEROZYGOSITY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; PHOSPHOPROTEINS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION;

EID: 8444227445     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826024     Document Type: Article

References (42)

1. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50: 191-197
2. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 1987; 30: 763-768
3. Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes 1990; 39: 1315-1319
4. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992
5. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study [see comments]. Lancet 1992; 340: 925-929
6. Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, de la Luz Sierra M, Suzuki Y, Koller E, Levy-Toledano R, Wertheimer E et al. Mutations in the insulin receptor gene. Endocr Rev 1992; 13: 566-595
7. Moller DE, Cohen O, Yamaguchi Y, Assiz R, Grigorescu F, Eberle A, Morrow LA, Moses AC, Flier JS. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 1994; 43: 247-255
8. Moller DE, Bjorbaek C, Vidal-Puig A. Candidate genes for insulin resistance. Diabetes Care 1996; 19: 396-400
9. Almind K, Doria A, Kahn CR. Putting the genes for type II diabetes on the map. Nat Med 2001; 7: 277-279
10. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352: 73-77
11. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF. Role of IRS-2 in insulin and cytokine signaling. Nature 1995; 377: 173-177
12. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22: 267-272
13. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 1994; 269: 3568-3573
14. Yeh JI, Gulve EA, Rameh L, Birnbaum MJ. The effects of wortmannin on rat skeletal muscle. Dissociation of signaling pathways for insulin- and contraction-activated hexose transport. J Biol Chem 1995; 270: 2107-2111
15. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling [published erratum appears in Biochem J 1998 Nov 1; 335 (Pt 3): 711]. Biochem J 1998; 333: 471-490
16. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling [published erratum appears in Biochem J 1998 Nov 1; 335 (Pt 3): 711]. Biochem J 1998; 333: 471-490
17. Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell 1991; 65: 75-82
18. Hu P, Margolis B, Skolnik EY, Lammers R, Ullrich A, Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 1992; 12: 981-990
19. Lamphere L, Carpenter CL, Sheng ZF, Kallen RG, Lienhard GE. Activation of PI 3-kinase in 3T3-L1 adipocytes by association with insulin receptor substrate-1. Am J Physiol 1994; 266: E486-494
20. Dhand R, Hues I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K et al. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. Embo J 1994; 13: 522-533
21. Otsu M, Hues I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 1991; 65: 91-104
22. Antonetti DA, Algenstaedt P, Kahn CR. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol Cell Biol 1996; 16: 2195-2203
23. Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR. Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 1997; 272: 23696-23702
24. Fruman DA, Cantley LC, Carpenter CL. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics 1996; 37: 113-121
25. Inukai K, Anai M, van Breda E, Hosaka T, Katagiri H, Funaki M, Fukushima Y, Ogihara T, Yazaki Y, Kikuchi M, Oka Y, Asano T. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85alpha gene. J Biol Chem 1996; 271: 5317-5320
26. Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, Myers MG Jr, Sun XJ, White M. F. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995; 15: 4453-4465
27. Flier JS, Young JB, Landsberg L. Familial insulin resistance with acanthosis nigricans, acral hypertrophy, and muscle cramps. N Engl J Med 1980; 303: 970-973
28. Dib K, Whitehead JP, Humphreys PJ, Soos MA, Baynes KC, Kumar S, Harvey T, O'Rahilly S. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998; 101: 1111-1120
29. Baynes KC, Beeton CA, Panayotou G, Stein R, Soos M, Hansen T, Simpson H, O'Rahilly S, Shepherd PR, Whitehead JP. Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. Diabetologia 2000; 43: 321-331
30. Kausch C, Hamann A, Uphues I, Niendorf A, Muller-Wieland D, Joost HG, Algenstaedt P, Dreyer M, Rudiger HW, Haring HU, Eckel J, Matthaei S. Association of impaired phosphatidylinositol 3-kinase activity in GLUT1 - containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome. J Clin Endocrinol Metab 2000; 85: 905-918
31. Hoepffner HJ, Dreyer M, Reimers U, Schmidt-Preuss U, Koepp HP, Rudiger HW. A new familial syndrome with impaired function of three related peptide growth factors. Hum Genet 1989; 83: 209-216
32. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
33. Katagiri H, Asano T, Ishihara H, Inukai K, Shibasaki Y, Kikuchi M, Yazaki Y, Oka Y. Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3- kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J Biol Chem 1996; 271: 16987-16990
34. Mendez R, Myers MG Jr, White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol Cell Biol 1996; 16: 2857-2864.
35. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994; 14: 4902-4911
36. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997; 46: 524-527
37. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95: 2195-2204
38. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1997; 94: 4171-4175
39. Hansen L, Echwald SM, Hansen T, Urhammer SA, Clausen JO, Pedersen O. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997; 46: 508-512
40. Hansen T, Andersen CB, Echwald SM, Urhammer SA, Clausen JO, Vestergaard H, Owens D, Hansen L, Pedersen O. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997; 46: 494-501
41. Baier LJ, Wiedrich C, Hanson RL, Bogardus C. Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women. Diabetes 1998; 47: 973-975
42. 326IIe variant of phosphatidylinositol 3- kinase p85alpha. Proc Natl Acad Sci USA 2002; 99: 2124-2128